Enclomiphene and Masteron Interaction: Synergistic | Peptide Database

Join others researching Vesugen — share findings, ask questions, and learn from real experiences Vesugen is a Khavinson bioregulator tripeptide developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology. Composed of three amino acids (lysine, glutamic acid, aspartic acid), it targets the vascular system and protects blood vessels from age-related decline. Research shows it limits atherosclerosis development, decreases endothelial dysfunction, and activates stem cells. Like other short Khavinson peptides, Vesugen penetrates to the nucleus where it influences gene expression. Vesugen works through epigenetic regulation by interacting with DNA promoter regions, particularly affecting Ki-67 gene expression which controls cell division. It plays a prominent role in regulating sirtuin 1 (SIRT1) protein levels - a key anti-aging protein activated during calorie restriction. Vesugen enhances mesenchymal stem cell proliferation, reduces senescence markers, improves cell differentiation, and may reverse the Senescence-Associated Secretory Phenotype (SASP) implicated in age-related cardiovascular disease.

FDA-approved for the treatment of primary hyperlipidemia and mixed dyslipidemia. Pitavastatin 2-4 mg provides clinically meaningful LDL reduction comparable to moderate-intensity atorvastatin or rosuvastatin. Particularly well-suited for patients on complex medication regimens where drug interactions are a concern. Used off-label to manage lipid disturbances caused by anabolic steroid cycles. Its primary advantage in this context is the absence of CYP3A4 interactions, meaning it can be safely co-administered with compounds, ancillaries, and other medications without dose adjustments or concerns about altered statin levels. The relatively stronger HDL-raising effect compared to other statins is an additional benefit given that HDL suppression is often the most resistant lipid abnormality during AAS use. The preferred statin choice for individuals with pre-existing insulin resistance, metabolic syndrome, or borderline glucose tolerance. The J-PREDICT trial showed pitavastatin actually reduced the incidence of new-onset diabetes by 18% compared to placebo, in contrast to other statins which modestly increase diabetes risk. This is particularly relevant for AAS users running compounds that affect glucose metabolism such as growth hormone or certain oral steroids. Appropriate for cardiovascular risk reduction in individuals with dyslipidemia and additional risk factors. While pitavastatin lacks the large-scale dedicated cardiovascular outcomes trial data that rosuvastatin and atorvastatin have (JUPITER, ASCOT), its class-effect benefits are well established and supported by the long-term LIVES study data from Japan. The statin of choice when drug interaction potential must be minimized. Especially relevant for individuals taking azole antifungals, macrolide antibiotics, protease inhibitors, or other CYP3A4 inhibitors that would significantly increase blood levels of atorvastatin or simvastatin. In the AAS context, this is advantageous for users running multiple compounds with hepatic metabolism.